Here are 1-3 brief analogies to describe Aura Biosciences:

• Moderna for cancer, but using virus-like particles as its core technology platform to deliver therapies.

• Seagen for ocular and urologic cancers, pioneering virus-like drug conjugates for precision treatment.

• AU-011: A virus-like drug conjugate (VDC) candidate being developed for the treatment of primary choroidal melanoma and other ocular oncology indications.
• VDC Technology Platform: A proprietary platform used to develop virus-like drug conjugate therapies for various cancers.

Aura Biosciences, Inc. (AURA) is a biotechnology company focused on the research and development of novel therapies for cancer. As a company primarily engaged in the development and clinical testing of drug candidates, such as AU-011 for choroidal melanoma, it does not currently have major customers in the traditional sense of selling commercial products or services to other companies or individuals. Its business model at this stage revolves around advancing its drug candidates through clinical trials with the goal of eventual regulatory approval and commercialization, either independently or through partnerships.

Elisabet de los Pinos, Chief Executive Officer

Elisabet de los Pinos is the founding CEO of Aura Biosciences, which she established in 2009. Prior to founding Aura, she worked in Eli Lilly & Co.'s oncology business unit, where she was part of the leadership team responsible for the market launch of Alimta, a drug for lung cancer, in Europe. Her earlier career included work as a research scientist in academia and big pharma, as well as post-doctoral fellowships at the Institute of Cancer Research in London, Mount Sinai School of Medicine Institute of Molecular Medicine, and Georgetown School of Medicine. Dr. de los Pinos holds a Ph.D. in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

Tony Gibney, Chief Financial and Business Officer

Tony Gibney is an experienced biotechnology leader and former investment banker with over 30 years of experience advising and leading biotechnology companies. His past roles include Chief Business Officer at Achillion Pharmaceuticals, Inc. and Iveric Bio, Inc., and Chief Business and Financial Officer at Fog Pharmaceuticals, Inc. Notably, Mr. Gibney was involved with Iveric Bio, Inc. which was acquired by Astellas Pharma Inc. in July 2023, and Achillion Pharmaceuticals, Inc. which was sold to Alexion Pharmaceuticals, Inc. in May 2020. He received a B.A. in Economics and History from Yale University.

Jill Hopkins, MD, Chief Medical Officer, President of Research & Development

Jill Hopkins, MD, was appointed Chief Medical Officer and President of Research & Development in October 2023. She brings over 30 years of cross-sector experience in ophthalmology, encompassing clinical care, academia, education, industry, advocacy, and innovation. Before joining Aura, Dr. Hopkins served as Senior Vice President, Global Head of Ophthalmology and Exploratory Development at Novartis, and was the Chief Executive Officer of Gyroscope Therapeutics, a Novartis company. She also spent over a decade at Roche-Genentech, with her most recent role there being Global Head Ophthalmology Personalized Health Care.

Conor Kilroy, Chief Legal Officer and Secretary

Conor Kilroy serves as Chief Legal Officer and Secretary at Aura Biosciences. Prior to Aura, Mr. Kilroy was general counsel and secretary at Neurogastrx, Inc. His experience also includes various roles at Ironwood Pharmaceuticals, Inc., including Senior Vice President, General Counsel, and earlier positions at Boston Scientific Corporation and Goodwin Procter LLP. Mr. Kilroy holds a J.D. from Boston College Law School and a B.A. from Brandeis University.

Mark Plavsic, PhD, Chief Technology Officer

Mark Plavsic, PhD, is the Chief Technology Officer at Aura, an appointment made in October 2023. He possesses 30 years of global biopharmaceutical experience in end-to-end technical operations. Before Aura, Dr. Plavsic served as Chief Technology Officer at Fate Therapeutics, a clinical-stage biopharmaceutical company, and previously held the same role at Lysogene, a late-stage gene therapy company. He also spent over 10 years at Sanofi Genzyme in Technical Operations and Technology Development & Manufacturing, where he led gene therapy development. Dr. Plavsic received his Ph.D. in Virology and Immunology and his DVM from the University of Belgrade.

1. Clinical Development and Regulatory Approval Risk

   Aura Biosciences' success is heavily dependent on the successful outcome of its clinical trials and the subsequent regulatory approval of its lead product candidate, AU-011 (bel-sar). The company is advancing AU-011 in various oncology indications, including a Phase 3 CoMpass trial for primary choroidal melanoma and earlier-stage trials for choroidal metastases and non-muscle invasive bladder cancer. Clinical trials are inherently uncertain, and there is a significant risk that AU-011 may not demonstrate sufficient safety or efficacy, may encounter unexpected adverse events, or may fail to meet primary or secondary endpoints. Even with positive clinical data, the company faces the risk of delays or failure to obtain necessary regulatory approvals from agencies like the FDA, which could prevent or postpone commercialization.

2. Funding and Cash Burn Risk

   As a clinical-stage biotechnology company, Aura Biosciences does not yet generate revenue from product sales and relies significantly on its existing cash reserves and its ability to raise additional capital. The company has a substantial cash burn rate to fund its ongoing research and development activities, particularly its costly clinical trials and manufacturing efforts. As of September 2025, the company had a cash runway of approximately 22 months, based on its cash burn over the trailing twelve months. There is a risk that Aura Biosciences may require additional funding sooner than anticipated, and its ability to secure such funding on favorable terms, or at all, is subject to market conditions and investor sentiment. Failure to obtain sufficient funding could force the company to delay, scale back, or discontinue its product development programs.

3. Competition and Market Acceptance Risk

   Aura Biosciences operates in a highly competitive oncology market. While AU-011 is being developed as a potential first-line treatment for primary choroidal melanoma with a focus on vision preservation, existing treatments like radiotherapy are established, despite their associated drawbacks such as significant vision loss. For AU-011 to achieve commercial success, it must demonstrate a compelling advantage in terms of efficacy, safety, and quality of life benefits over current standards of care to gain market acceptance from physicians, patients, and payers. Furthermore, other companies may be developing competing therapies, including novel approaches, which could impact AU-011's market potential.

• For **primary choroidal melanoma**, the addressable market in the U.S. and Europe is approximately 11,000 patients annually. Within the U.S., an estimated 600 "small melanomas" and 3,900 "indeterminate lesions" diagnosed each year are considered suitable for AU-011.
• For **choroidal metastases**, there are approximately 22,000 patients annually in the United States and Europe. Globally, the number of patients with choroidal metastasis is also estimated at around 22,000 per year.

Share Issuance

• Aura Biosciences priced its Initial Public Offering (IPO) on October 28, 2021, offering 5,400,000 shares of common stock at $14.00 per share, which was expected to generate gross proceeds of $75.6 million.
• On November 30, 2022, the company announced the pricing of an underwritten public offering of 6,700,000 shares of common stock at $12.00 per share, with expected gross proceeds of $80.4 million.
• In May 2025, Aura Biosciences priced an underwritten public offering, including 11,735,565 shares of common stock and accompanying warrants, with anticipated gross proceeds of $75.0 million.

Inbound Investments

• Aura Biosciences has raised a total of $215 million across 11 funding rounds.
• The company secured a $21 million Series B funding round, led by Advent Life Sciences, with participation from new investors Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments.
• An additional $8 million round of funding was secured from existing investors, including Advent Partners, Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments.

Capital Expenditures

• Aura Biosciences anticipates that its current cash, cash equivalents, and marketable securities will be sufficient to fund operating expenses and capital expenditures into the second half of 2026.
• Capital expenditures are primarily focused on advancing clinical programs, including the global Phase 3 CoMpass trial for early choroidal melanoma, other ocular oncology indications, and bladder cancer.
• The company expects increased expenses as it progresses its global Phase 3 trial of bel-sar in early choroidal melanoma and due to higher personnel costs related to company growth.